Toripalimab Plus Lenalidomide for Central Nervous System Recurrence in Refractory CD5 Diffuse Large B-cell Lymphoma with and Comutation: a Case Report

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Mar 14

PMID 38482415

Authors

Xi Chen

Zhihan Zhang

Junbao Zhang

Qiuxiao Yu

Junjing Qiu

Yajie Xiao

Binbin Chen

Ping Xu

Affiliations

Soon will be listed here.

Abstract

Background: CD5-positive (CD5) non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL) is heterogeneous with a poor prognosis. For refractory DLBCL, the median overall survival was only 6.3 months. Therefore, there is a need for approaches to elongate the survival in this subgroup of relapsed DLBCL patients.

Case Description: Here, we present a rare case of a 72-year-old patient with stage IV CD5 non-GCB DLBCL with myeloid differentiation primary response 88 () and cluster of differentiation 79B () comutations. Zanubrutinib and rituximab therapy was initially administered until disease progression. Subsequently, zanubrutinib plus rituximab together with attenuated standard chemotherapy (miniCHOP) was applied and a notable response was observed. The patient tolerated the treatment well and exhibited a complete response in lung for about 5 months. Afterwards, the patients experienced relapse in the brain and started programmed death protein 1 (PD-1) regimens of toripalimab plus lenalidomide, which also exhibited a good response with decreased lesions in brain after half-year treatment. However, the patient experienced relapse again in the brain 3 months later and started chemotherapy with methotrexate plus rituximab. The patient had survived for over 2 years since the initial diagnosis of stage IV DLBCL and has continued to survive after experiencing a relapse in the brain for approximately 11 months till now.

Conclusions: These findings suggest that toripalimab may be a new therapeutic option for central nervous system recurrence in refractory CD5 DLBCL with and comutation. Further clinical trials are warranted to confirm these results.

References

Heimann P, Dewispelaere L . Indications of next-generation sequencing in non-Hodgkin's lymphoma. Curr Opin Oncol. 2020; 32(5):391-397. DOI: 10.1097/CCO.0000000000000666. View

Bastos-Oreiro M, Suarez-Gonzalez J, Andres-Zayas C, Carrion N, Moreno S, Carbonell D . Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin's lymphoma. Sci Rep. 2021; 11(1):22815. PMC: 8613247. DOI: 10.1038/s41598-021-02362-4. View

Wilson W, Wright G, Huang D, Hodkinson B, Balasubramanian S, Fan Y . Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021; 39(12):1643-1653.e3. PMC: 8722194. DOI: 10.1016/j.ccell.2021.10.006. View

Wilson W, Young R, Schmitz R, Yang Y, Pittaluga S, Wright G . Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015; 21(8):922-6. PMC: 8372245. DOI: 10.1038/nm.3884. View

Visco C, Tanasi I, Quaglia F, Ferrarini I, Fraenza C, Krampera M . Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice. Cancers (Basel). 2020; 12(10). PMC: 7600909. DOI: 10.3390/cancers12102913. View

Lin X, Cai Y, Zong C, Chen B, Shao D, Cui H . Bronchoalveolar Lavage as Potential Diagnostic Specimens to Genetic Testing in Advanced Nonsmall Cell Lung Cancer. Technol Cancer Res Treat. 2023; 22:15330338231202881. PMC: 10521282. DOI: 10.1177/15330338231202881. View

Ma D, Ma Y, Ma Y, Liu J, Gu Y, Liu N . Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx. Front Oncol. 2022; 12:941347. PMC: 9445310. DOI: 10.3389/fonc.2022.941347. View

Jiang S, Qin Y, Jiang H, Liu B, Shi J, Meng F . Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. Int J Cancer. 2020; 147(9):2611-2620. DOI: 10.1002/ijc.33049. View

Zhang L, Hao B, Geng Z, Geng Q . Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022; 12:730666. PMC: 8789657. DOI: 10.3389/fimmu.2021.730666. View

10.

Xu-Monette Z, Zhou J, Young K . PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2017; 131(1):68-83. PMC: 5755041. DOI: 10.1182/blood-2017-07-740993. View

11.

Liu Y, Barta S . Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019; 94(5):604-616. DOI: 10.1002/ajh.25460. View

12.

Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

13.

Rovira J, Karube K, Valera A, Colomer D, Enjuanes A, Colomo L . MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. Clin Cancer Res. 2016; 22(11):2755-64. DOI: 10.1158/1078-0432.CCR-15-1525. View

14.

Greve P, Meyer-Wentrup F, Peperzak V, Boes M . Upcoming immunotherapeutic combinations for B-cell lymphoma. Immunother Adv. 2022; 1(1):ltab001. PMC: 9326875. DOI: 10.1093/immadv/ltab001. View

15.

Mabuchi F, Sakurada Y, Kashiwagi K, Yamagata Z, Iijima H, Tsukahara S . Involvement of genetic variants associated with primary open-angle glaucoma in pathogenic mechanisms and family history of glaucoma. Am J Ophthalmol. 2014; 159(3):437-44.e2. DOI: 10.1016/j.ajo.2014.11.023. View

16.

Witzig T, Nowakowski G, Habermann T, Goy A, Hernandez-Ilizaliturri F, Chiappella A . A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol. 2015; 26(8):1667-77. DOI: 10.1093/annonc/mdv102. View

17.

Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M . Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2015; 42(3):279-90. DOI: 10.1111/nan.12259. View

18.

Ollila T, Kurt H, Waroich J, Vatkevich J, Sturtevant A, Patel N . Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma. Blood. 2020; 137(8):1120-1124. PMC: 8215190. DOI: 10.1182/blood.2020007236. View

19.

Lipsky A, Lamanna N . Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020; 2020(1):336-345. PMC: 7727553. DOI: 10.1182/hematology.2020000118. View

20.

Phelan J, Young R, Webster D, Roulland S, Wright G, Kasbekar M . A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018; 560(7718):387-391. PMC: 6201842. DOI: 10.1038/s41586-018-0290-0. View